Fluid retention and heart failure: Rosiglitazone can cause fluid retention in the body and cause heart failure or worsen existing heart failure. During treatment with rosiglitazone is necessary to control body weight and watch for signs that indicate fluid retention. In each case it is necessary to find out the cause of increase in body weight and the role of water retention. The rapid and significant increase in body weight caused by a delay in the body fluid, is rare. Monitoring for signs of heart failure is particularly dianabol review important in the case of reduced cardiac reserve capacity. At any sign of deterioration in cardiac status of treatment with rosiglitazone should be discontinued.
Monitoring of liver function is required during treatment with rosiglitazone, as in rare cases develop abnormal liver function. Before starting treatment with rosiglitazone should determine the original activity of “hepatic” enzymes. With their increase (increase in the top rate of alanine aminotransferase in 2.5 times) or the development of other signs of liver damage can not provide treatment with rosiglitazone. In the first year of treatment with rosiglitazone liver function should be monitored every 2 months, you can later with some frequency. In the case of increasing the level of alanine aminotransferase in the course of treatment up to the level of 3 times the upper limit of normal, should immediately conduct an extraordinary inspection in the case of the progression of symptoms of treatment with rosiglitazone should be discontinued.
In case of any symptoms suggestive dianabol review of liver disease, including nausea of unknown etiology, vomiting, abdominal pain, fatigue, anorexia and / or dark urine staining, should be re-measure the level of “hepatic” enzymes. On the possibility of continuing rosiglitazone therapy decide on the basis of laboratory parameters. Jaundice is an indication for discontinuation of treatment.
Weight gain: During treatment should periodically measure the patient’s body weight due to possible water retention in the body.
Anemia: Treatment may be accompanied by a decrease in hemoglobin level. When initially low hemoglobin likely to develop anemia more.
Other: With an increase in insulin sensitivity in women with anovulation caused by insulin resistance, may restore ovulation. It should warn patients of the possibility of conception, and if the patient wishes to continue the pregnancy treatment with rosiglitazone should be discontinued. Concomitant use of paclitaxel requires caution.
In the case of lactose intolerance should be noted that the tablet 2, 4, and 8 mg of rosiglitazone, respectively, contain 54.403 mg 108.806 mg 217.612 mg lactose.
Effects on ability to drive and other machines: rosiglitazone dianabol review has no effect on ability to drive and other machines.